(Q37622889)

21 August 2017

1 reference

title

Ixiaro: a new vaccine against Japanese encephalitis (English)

1 reference

Japanese encephalitis virus

21 August 2017

0 references

author name string

Tomas Jelinek

series ordinal

1

1 reference

21 August 2017

1 November 2009

1 reference

Expert Review of Vaccines

21 August 2017

1 reference

21 August 2017

8

1 reference

21 August 2017

11

1 reference

21 August 2017

1501-1511

1 reference

Flavivirus genome organization, expression, and replication

21 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Japanese encephalitis for a reference to international travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

A decade of Japanese encephalitis surveillance in Sarawak, Malaysia: 1997-2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

A hospital-based surveillance for Japanese encephalitis in Bali, Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Expert opinion on vaccination of travelers against Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Japanese encephalitis in travelers: review of cases and seasonal risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Control of Japanese encephalitis--within our grasp?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Japanese encephalitis in a Finnish traveler on a two-week holiday in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Genetic variation of Japanese encephalitis virus in nature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Japanese encephalitis vaccine in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Protection against Japanese encephalitis by inactivated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Further experience with Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Acute disseminated encephalomyelitis after Japanese B encephalitis vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Side-effects with Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Adverse reactions to Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Adverse reactions to Japanese encephalitis vaccine in travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Current use and development of vaccines for Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-hu

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis anti

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Comparison of nucleotide and deduced amino acid sequence of the 5' non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

IC51 Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Japanese encephalitis vaccine (inactivated, adsorbed) [IXIARO].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Allergic reactions to Japanese encephalitis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Acute disseminated encephalomyelitis after treatment with Japanese B encephalitis vaccine (Nakayama-Yoken and Beijing strains).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Systemic allergic reactions to Japanese encephalitis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Japanese encephalitis vaccine for travelers: exploring the limits of risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

Vaccines in travel health: from risk assessment to priorities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

A case of imported JE acquired during short travel in Vietnam. Are current recommendations about vaccination broader?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.09.112

21 January 2018

Identifiers

DOI

10.1586/ERV.09.112

1 reference

21 August 2017

1 reference

PubMed ID

19863241